WO2023105051 - CANCER THERAPY TARGETING EGFR
National phase entry is expected:
Publication Number
WO/2023/105051
Publication Date
15.06.2023
International Application No.
PCT/EP2022/085198
International Filing Date
09.12.2022
Title **
[English]
CANCER THERAPY TARGETING EGFR
[French]
THÉRAPIE CONTRE LE CANCER CIBLANT L'EGFR
Applicants **
LES LABORATOIRES SERVIER
35 rue de Verdun
92284 SURESNES, FR
Inventors
PALLIS, Athanasios
17 rue Juge
75015 PARIS, FR
Priority Data
21306751.5
10.12.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2228 | |
| EPO | Filing, Examination | 15053 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 11310 |
Total: 29755 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A combination comprising (a) an anti-EGFR antibody component comprising one or two anti-EGFR antibodies or antigen-binding portions thereof and (b) a trifluridine/tipiracil component.[French]
L'invention concerne une combinaison comprenant (A) un composant anticorps anti-EGFR comprenant un ou deux anticorps anti-EGFR ou des parties de liaison à l'antigène de celui-ci et (b) un composant trifluridine/tipiracil.